Figure 4.
Change in 6MWD and change in PVR with oral treprostinil therapy. No significant improvement in PVR was seen in the group as a whole or in any tested subgroup. Circles in the top plot indicate outliers. CTD: connective-tissue disease; epo: epoprostenol; IQ: interquartile; IV Rx: intravenous therapy; PVR: pulmonary vascular resistance; SD: standard deviation; tre: treprostinil; 6MWD: 6-minute walk distance. *Last PO tre: last catheterization while still receiving oral treprostinil.